BB Biotech in 60 seconds

BB Biotech in 60 seconds

BB Biotech — 1 video in collection

More on this equity

The biotech sector has been hit by uncertainties about the economic outlook, US tariffs and the regulatory policies of the new US administration. This has increased market volatility, especially in the small- and mid-cap companies that BB Biotech favours and performance has declined accordingly. Yet the news is not all bad. The company’s portfolio holdings are performing well, with several delivering regulatory and clinical milestones. BB Biotech’s manager has taken action to protect returns by increasing the focus on larger-cap names and enhancing risk management. Lower valuations have created opportunities for the trust’s manager to gain exposure to more high-quality companies. Most importantly, the biotech sector still has a positive long-term outlook, with commensurate rewards for those willing to wait out near-term volatility.


You may also be interested in these:

Investment Companies

Gresham House Energy Storage Fund in 60 seconds

Investment Companies

Take on Trusts – May 2025

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free